Every 10-Q that Entera Bio Ltd. (ENTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTX filings page.
Entera Bio Ltd., a clinical-stage developer of oral peptide therapies, reported higher losses as it advanced its lead osteoporosis candidate EB613 and partnered programs EB612 and EB618. For the six months ended June 30, 2026, the company recorded no revenue, research and development expenses of $5.5 million and a net loss of $10.8 million, up from $5.2 million a year earlier, driven by increased development spending and a non-cash remeasurement of pre-funded warrant liabilities.
Cash, cash equivalents and restricted cash totaled $18.5 million at June 30, 2026. In July 2026, Entera completed a private placement raising about $275 million, and the company states that, together with existing cash, this is expected to fund planned operations, including a single Phase 3 EB613 trial in roughly 750 postmenopausal women with osteoporosis and continued advancement of EB612 and EB618 with OPKO, into 2030.
Entera Bio Ltd. reported a Q1 2026 net loss of $3.5 million, up 37% from Q1 2025, driven mainly by higher research and development spending as its oral peptide pipeline advances.
Revenue was zero in Q1 2026 compared with $42 thousand a year earlier, reflecting completion of a prior research services agreement. Research and development expenses rose to $2.3 million, a 100% increase, as the company invested in EB613 Phase 3 preparation and its OPKO collaboration programs EB612 and EB618. General and administrative costs edged down 11% to $1.3 million.
As of March 31, 2026, Entera held $11.9 million in cash, cash equivalents and restricted cash, including $7.8 million earmarked for its OPKO collaboration. A private placement completed in April 2026 added approximately $10.0 million in gross proceeds. Even with this financing, management states that current resources are expected to fund operations only through the first quarter of 2027 and do not fully cover the planned Phase 3 osteoporosis program for EB613, leading to substantial doubt about the company’s ability to continue as a going concern without additional capital.
Entera Bio (ENTX) filed its Q3 2025 10‑Q, showing a clinical-stage profile with minimal revenue and ongoing losses. For the nine months ended September 30, 2025, revenue was $42 thousand and net loss was $8.4M (loss per share $0.18). In Q3, net loss was $3.2M.
Cash, cash equivalents and restricted cash totaled $16.7M at quarter‑end, including $8.0M held in escrow from OPKO’s equity purchase tied to the 2025 collaboration. Operating cash use was $5.5M year‑to‑date. R&D was $4.3M and G&A $4.2M for the period.
Management states substantial doubt about continuing as a going concern. The company believes existing cash supports operations through the middle of Q3 2026, but starting the EB613 Phase 3 program will require additional funding. The FDA agreed that a single 24‑month Phase 3 with total hip BMD as the primary endpoint could support an NDA for EB613, letting the program advance. Capital actions included net ATM proceeds of $6.1M (2,731,574 shares at a weighted average price of $2.29) and the issuance of 3,685,226 shares to OPKO for $8.0M (escrowed).
Shares outstanding were 45,664,506 as of September 30, 2025, and 45,857,242 as of November 10, 2025.
Entera Bio Ltd. reported consolidated cash, cash equivalents and restricted cash of $18.9 million as of June 30, 2025, up from $9.1 million a year earlier, driven by equity financings and a collaboration payment held in escrow. The company recorded a six‑month net loss of $5.2 million (loss per share $0.12), increasing R&D spend to $2.6 million as it prepares for an EB613 Phase 3 program and advances the OPKO collaboration on oral OXM.
Management states available funds should support operations through the middle of the third quarter of 2026 under current plans but excludes the capital required to initiate the EB613 Phase 3 study, and the filing notes this raises substantial doubt about the company’s ability to continue as a going concern. Material near‑term developments include a $8.0 million issuance to OPKO (3,685,226 shares) placed in escrow to fund collaborative program costs and the FDA’s written concurrence (July 28, 2025) that a single 24‑month multinational Phase 3 with total hip BMD primary endpoint can support an NDA for EB613.